In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational ...

Last Friday, Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined significantly when compared to the previous year. Adjusted loss was ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Moderna (NASDAQ:MRNA – Get Free Report) had its target price decreased by investment analysts at UBS Group from $96.00 to $78.00 in a research note issued to investors on Wednesday,Benzinga reports.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.